Related references
Note: Only part of the references are listed.Treatment of hepatitis C virus genotype 3-infection
Stanislas Pol et al.
LIVER INTERNATIONAL (2014)
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Mark S. Sulkowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C Results From an Analysis of Data From a Department of Veterans Affairs Clinical Registry
Jeffrey McCombs et al.
JAMA INTERNAL MEDICINE (2014)
In Vitro Activity of Daclatasvir on Hepatitis C Virus Genotype 3 NS5A
Chunfu Wang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors
Dennis Hernandez et al.
JOURNAL OF CLINICAL VIROLOGY (2013)
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Antiviral activity and resistance of HCV NS5A replication complex inhibitors
Min Gao
CURRENT OPINION IN VIROLOGY (2013)
HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis
G. Nkontchou et al.
JOURNAL OF VIRAL HEPATITIS (2011)
The global health burden of hepatitis C virus infection
Francesco Negro et al.
LIVER INTERNATIONAL (2011)
Hepatitis C Virus Genotype 3 and the Risk of Severe Liver Disease in a Large Population of Drug Users in France
Christine Larsen et al.
JOURNAL OF MEDICAL VIROLOGY (2010)
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C
Pierre-Yves Bochud et al.
JOURNAL OF HEPATOLOGY (2009)
Share Paper
